Cancer Moonshot to Bring Hope to Desperate Cancer Patients
Published: 2023-03-25
Page: 68-73
Issue: 2023 - Volume 6 [Issue 1]
Ming C. Liau *
CDA Therapeutics, Inc. 3308 Sky Run Court, Missouri City, TX 77459, USA.
Christine L. Craig
CDA Therapeutics, Inc. 3308 Sky Run Court, Missouri City, TX 77459, USA.
Linda L. Baker
CDA Therapeutics, Inc. 3308 Sky Run Court, Missouri City, TX 77459, USA.
*Author to whom correspondence should be addressed.
Abstract
It was very sad to learn that President Jimmy Carter and Jane Fonda have given up fights to battle cancer. Terminal stage cancer patients all end up like these two very distinguished figures hopeless to carry on fighting. At terminal stage, patient’s cancer cells (CCs) are loaded with cancer stem cells (CSCs) unresponsive to therapies currently in practice, which are actually responsible for the creation of hopeless situation. Perpetual replication of CCs is the most outstanding feature of cancer. Naturally, killing of replicating CCs becomes the top choice of cancer establishments to combat cancer. Killing of replicating CCs is actually a wrong approach of cancer therapy, because cancer is caused by wound not healing properly. Wound creates symptom, and healing is an effort to eliminate the symptom created by the wound. Wound healing requires the proliferation and the terminal differentiation of progenitor stem cells (PSCs) [1-3]. Terminal differentiation of PSCs is the most important mechanism of wound healing, because only terminally differentiated cells can restore biological function damaged by the wound. Thus, terminal differentiation of PSCs is the critical mechanism to dictate the success of wound healing. If wound is not healed properly, the symptom created by the wound will force PSCs to keep on replicating, but the replication of PSCs is limited by the rule of contact inhibition. PSCs are normal stem cells which obey the rule of contact inhibition. They are then forced to evolved into CSCs to escape contact inhibition, and then to progress to faster growing CCs. Henceforth, the replication of CSCs and CCs is an effort to heal the wound. Promotion of terminal differentiation of CSCs and CCs is, therefore, the right approach of cancer therapy [4].
The hopeless situation of terminal cancer patients is the result of wrong therapies put forth by cancer establishments. Cancer arises due to the collapse of chemo-surveillance which is a mechanism created by the nature to ensure perfection of wound healing to avoid cancer. The functionality of chemo-surveillance has been badly damaged for the symptom of cancer to show up. Cytotoxic agents further aggravate the already badly damaged chemo-surveillance by creating more wounds. Killing of CCs also triggers CSCs to proliferate to heal the damages created by cytotoxic agents. In the end, CCs are replaced by CSCs which are not responding to cytotoxic agents, because these cells are protected by drug resistance and anti-apoptosis mechanisms. Restoration of chemo-surveillance is an effective measure to limit the build up of CSCs [5]. Development of CDA formulations to restore the functionality of chemo-surveillance is a right remedy to correct the mistakes created by cancer establishments [6-12]. Cancer establishments were definitely not doing the things right to fail the challenge of war on cancer. They continued to use the failed strategy on killing of CCs to cause deaths of cancer patients [13,14]. There is no mechanism within the health profession to correct the mistakes made by cancer establishments. President Biden was genuinely committed to save cancer patients to declare cancer moonshot initiative. He has the authority to replace leaderships of federal health agencies to correct the mistakes of cancer establishments to bring hope to desperate cancer patients.
Keywords: Cancer moonshot, wound healing, CSCs, PSCs, cancer therapy
How to Cite
Downloads
References
Liau MC, Baker LL. Wound healing, evolution of cancer and war on cancer. Intl Res J Oncol. 2021;4(3):13-20.
Liau MC, Craig CL. On the mechanism of wound healing and the impact of wound on cancer evolution and cancer therapy. Intl Res J Oncol. 2021;5(3):25-31.
Liau, MC, Craig CL. No scar as an indication of perfect wound healing, ugly scar as imperfect wound healing and cancer as failed wound healing. J Cancer Tumor Intl. 2022;12(1):29-34.
Liau MC, Craig CL. Baker LL. Wound healing process as the most appropriate modality of cancer therapy. Eur J Applied Sci. 2023;11(1):463-471.
Liau MC, Fruehauf JP. Restoration of chemo-surveillance capability is essential for the success chemotherapy and radiotherapy to put cancer away. Adv Complement Alt Med. 2019;5(4):474-475.
Liau MC, Fruehauf PA, Zheng ZH, Fruehauf JP. Development of synthetic cell differentiation agent formulations for the prevention and therapy of cancer via targeting of cancer stem cells. Cancer Stu Ther J. 2019;4(1):1-15.
Liau MC, Kim JH, Fruehauf JP. Destabilization of abnormal methylation enzymes to combat cancer: The nature’s choice to win the war on cancer. Lambert Academic Publishing; 2020.
International Book Market Service Ltd, 978-620-2-66889-7.
Liau MC, Kim JH, Fruehauf JP. Destabilization of abnormal methylation enzymes: The nature’s way to eradicate cancer stem cells. Online J Complement Alt Med; 2019. DOI: 10.33552/OJCAM.2019.02.000546
Liau, MC, Fruehauf JP. The winner of the contest to eradicate cancer stem cells win the contest of cancer therapies: The winner is cell differentiation agent formulations. Adv Complement Alt Med. 2020;5(4):476-478.
Liau MC, Baker LL. Eradication of cancer stem cells to win the war on cancer. Nov Res Sci. 2021;6(5):1-3.
Liau MC, Baker LL. Cell differentiation agent formulations to win the war on cancer. Cancer Sci Res. 2022;5(2):1-4.
Liau MC, Fruehauf JP. Winning formulas to fulfill cancer moonshot. Intl J Res Oncol. 2022;1(1):1-5.
Liau MC, Fruehauf JP. Think hard on the destabilization of abnormal methylation enzymes to combat cancer. It can be life saving. Adv Complement Alt Med. 2019;5: 464-465.
Liau MC, Baker LL. Cancer patients’ lives matter. Adv Complement Alt Med. 2021;6(5):439-440.
Liau MC, Craig CL. Wound healing metabolites to heal cancer and unhealed wounds. Intl Res J Oncol. 2022;6:8-20.
Mongeri-Sacca M, Dimrino S, De Maria R. Biological and clinical implication of cancer stem cells in primary brain tumors. Front Oncol. 2013;3:6.
Nyce J, Liu J, Jones PA. Variable effects of DNA synthesis inhibitors upon DNA methylation in mammalian cells. Nucleic Acid Res. 1986;14(10):4353- 4367.
Nyce J. Drug-induced DNA hypermethylation and drug resistance in human tumors. Cancer Res. 1989;49(21): 5829-5836.
Virchow R. Die cellular pathologic in ihrer begrundung auf physiologische und pathologische gewebelelive. Hirschwald. 1858;16:440.
Dvorak HF. Tumors: Wounds that do not heal. N Engl J Med. 1986;315(26):1650-1659.
MacCarthy-Morrough L, Martin P. The hallmarks of cancer are also the hallmarks of wound healing. Science Signaling. 2020;13:648.
Liau MC, Lin GW, Hurlbert RB. Partial purification and characterization of tumor and liver S-adenosylmethionine synthetases. Cancer Res. 1977;37(2):427-435.
Liau MC, Chang CF, Giovanella BC. Demonstration of an altered S-adenosylmethionine synthetase in malignant human tumors xenografted into athymic nude mice. J Natl Cancer Inst. 1980;64(5):1071-1075.
Liau MC, Zhuang P, Chiou GCY. Identification of the tumor factor of abnormal methylation enzymes as the catalytic subunit of telomerase. Clin Oncol Cancer Res. 2010;7(2):86-96.
Liau MC, Szopa M, Burzynski B, et al. Chemo-surveillance: A novel concept of the natural defense mechanism against cancer. Drug Exptl Clin Res. 1989;13 (Suppl. 1):72-82.
Liau MC, Baker LL. The functionality of chemo-surveillance dictates the success of wound healing as well as cancer therapy. Nov Res Sci. 2021;7(2):1-3.
Liau MC, Craig CL. Chemo-surveillance as a natural mechanism to ensure perfection of wound healing to avoid cancer evolution and to cure cancer. In: New Horizons in Medicine and Medical Research. 2022;6, Chapter 3. Print ISBN: 978-93-5547-607-4.
Liau MC. Lee SS, Burzynski SR. Hypomethylaiton of nucleic acids: a key to the induction of terminal differentiation. Intl J Exptl Clin Chemother. 1988;9(2):187-199.
Kudo T, Tateishi K, Yamamoto S, et al. Loss of 5-hydroxymethylcytosine is accompanied with malignant cellular transformation. Cancer Sci. 2012;103(4): 670-676.
Ficz GM, Bibben JG. Loss of 5-hydroxymethylcytocine in cancer: cause or consequence? Genomics. 2014;104(5): 352-357.
Liau MC. Pharmaceutical composition inducing cancer cell differentiation and the use for the treatment and prevention of cancer thereor. US Patent 7232578 B2; 2007.
Woll PS, Kjallquist U, Chowdhurdy O, et al. Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cell in vivo. Cancer Cell. 2014;25(6):794-808.